| NCT06470451 | Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL | RECRUITING | PHASE3 | 2025-01-07 | 2026-10 | 2026-07 |
| NCT06386744 | Dusquetide for the Treatment of Behcet's Disease | COMPLETED | PHASE2 | 2024-11-18 | 2025-06-17 | 2025-05-23 |
| NCT06149247 | HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL | COMPLETED | PHASE2 | 2023-12-05 | 2024-06-27 | 2024-05-31 |
| NCT05442190 | Topical SGX302 for Mild-to-Moderate Psoriasis | RECRUITING | PHASE2 | 2022-12-14 | 2025-12 | 2025-10 |
| NCT05380635 | PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma | COMPLETED | PHASE2 | 2022-05-09 | 2022-08-16 | 2022-08-16 |
| NCT03237325 | DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer | COMPLETED | PHASE3 | 2017-12-04 | 2021-06-24 | 2020-06-24 |
| NCT02448381 | FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) | COMPLETED | PHASE3 | 2015-12 | 2020-11 | 2020-06 |
| NCT01925950 | Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD) | TERMINATED | PHASE2 | 2013-12 | 2015-05 | 2015-05 |
| NCT02013050 | A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer | COMPLETED | PHASE2 | 2013-12 | 2016-09 | 2015-12 |
| NCT01073384 | A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer | COMPLETED | PHASE1, PHASE2 | 2009-12 | 2012-11 | 2012-01 |
| NCT00926575 | Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD) | TERMINATED | PHASE3 | 2009-10 | 2012-05 | 2011-12 |